218 related articles for article (PubMed ID: 25553837)
1. Long-term safety of tocilizumab treatment on chronic active hepatitis C in a patient with adult onset Still's disease.
Forestier E; Pasquali JL
Joint Bone Spine; 2015 Mar; 82(2):136-7. PubMed ID: 25553837
[No Abstract] [Full Text] [Related]
2. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Y; Kameda H; Ikeda K; Ishii T; Murakami K; Takamatsu H; Tanaka Y; Abe T; Takeuchi T
Ann Rheum Dis; 2018 Dec; 77(12):1720-1729. PubMed ID: 30279267
[TBL] [Abstract][Full Text] [Related]
3. A SEVERE CASE OF ADULT ONSET STILLS DISEASE WITH MYOPERICARDITIS, RESISTANT TO TREATMENT WITH TOCILIZUMAB BUT RESPONSIVE TO ANAKINRA.
Waghmare S; Valecka B; Cairns AP
Ulster Med J; 2015 May; 84(2):130-2. PubMed ID: 26376493
[No Abstract] [Full Text] [Related]
4. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis.
Kishida D; Okuda Y; Onishi M; Takebayashi M; Matoba K; Jouyama K; Yamada A; Sawada N; Mokuda S; Takasugi K
Mod Rheumatol; 2011 Apr; 21(2):215-8. PubMed ID: 20931272
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease.
Vandemergel X; Vandergheynst F
Acta Medica (Hradec Kralove); 2016; 59(1):22-5. PubMed ID: 27131353
[TBL] [Abstract][Full Text] [Related]
6. Relationship between earlier introduction of tocilizumab and glucocorticoid-sparing effects on the acute phase of adult-onset Still's disease.
Yoshihara R; Tsuchiya H; Shoda H; Fujio K
Scand J Rheumatol; 2024 Jul; 53(4):284-287. PubMed ID: 38314790
[No Abstract] [Full Text] [Related]
7. Efficacy of sarilumab in adult-onset Still's disease as a corticosteroid-sparing agent.
Simeni Njonnou SR; Soyfoo MS; Vandergheynst FA
Rheumatology (Oxford); 2019 Oct; 58(10):1878-1879. PubMed ID: 31056689
[No Abstract] [Full Text] [Related]
8. Adult-onset Still's disease in a patient with cystic fibrosis and its successful treatment with anakinra.
Albersmeyer MP; Hilge RG; Schulze-Koops H; Sitter T
Rheumatology (Oxford); 2012 Sep; 51(9):1730-2. PubMed ID: 22513144
[No Abstract] [Full Text] [Related]
9. Early use of anakinra in adult-onset Still's disease myocarditis.
Piel-Julian ML; Moulis G; Fournier P; Dupont R; Geiger D; Astudillo L; Faurie T; Pozzo J; Petermann A; Lairez O; Pugnet G; Sailler L
Scand J Rheumatol; 2018 Nov; 47(6):511-512. PubMed ID: 29291663
[No Abstract] [Full Text] [Related]
10. Interleukin-1 Inhibitors and Dacryoadenitis in Adult-Onset Still Disease.
Breillat P; Tourte M; Romero P; Hayem G; Padovano I; Costantino F; Breban M
Ann Intern Med; 2018 Mar; 168(6):455-456. PubMed ID: 29230477
[No Abstract] [Full Text] [Related]
11. Long-term efficacy and safety of Anakinra in a patient with liver transplant due to Adult onset Still's Disease.
Yilmaz S; Cinar M; Simsek I; Erdem H; Pay S
Mod Rheumatol; 2014 Nov; 24(6):1030-1. PubMed ID: 24313885
[No Abstract] [Full Text] [Related]
12. Rituximab treatment for pulmonary arterial hypertension in adult-onset Still's disease.
Padilla-Ibarra J; Sanchez-Ortiz A; Sandoval-Castro C; Ramos-Remus C
Clin Exp Rheumatol; 2013; 31(4):657-8. PubMed ID: 23622421
[No Abstract] [Full Text] [Related]
13. [CME: Adult Still disease].
Etter M; Vallelian F; Herfs G
Praxis (Bern 1994); 2015 Oct; 104(21):1117-25. PubMed ID: 26463902
[No Abstract] [Full Text] [Related]
14. Tocilizumab in adult-onset Still's disease: the Israeli experience.
Elkayam O; Jiries N; Dranitzki Z; Kivity S; Lidar M; Levy O; Ablin J; Abu-Shakra M; Savargyl-Maman H; Padova H; Caspi D; Rosner I
J Rheumatol; 2014 Feb; 41(2):244-7. PubMed ID: 24429168
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab.
Yamada H; Kaneko Y; Tamai H; Takeuchi T
Rheumatology (Oxford); 2020 Feb; 59(2):440-442. PubMed ID: 31504968
[No Abstract] [Full Text] [Related]
16. [Tocilizumab effectiveness in adult Still's disease].
López Buitrago R; Estrada Dorronsoro S; Cervera Segura R; Espinosa Garriga G
Med Clin (Barc); 2012 Jan; 138(1):42-3. PubMed ID: 21605875
[No Abstract] [Full Text] [Related]
17. Efficacy of tocilizumab in refractory adult-onset Still's disease; report of 2 cases.
Andrade-Ortega L; Irazoque-Palazuelos F; Muñoz-López S; Rosales-Don Pablo VM
Reumatol Clin; 2014; 10(3):199-200. PubMed ID: 24076178
[No Abstract] [Full Text] [Related]
18. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease.
Bannai E; Yamashita H; Kaneko S; Ueda Y; Ozaki T; Tsuchiya H; Takahashi Y; Kaneko H; Kano T; Mimori A
Mod Rheumatol; 2016; 26(2):297-301. PubMed ID: 24697199
[TBL] [Abstract][Full Text] [Related]
19. Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort.
Ruscitti P; Cipriani P; Liakouli V; Iacono D; Pantano I; Caso F; Perosa F; Atzeni F; Cantatore FP; Scarpa R; Ciccia F; Giacomelli R
Rheumatol Int; 2020 Jan; 40(1):107-113. PubMed ID: 31263993
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD).
Yoshimura M; Makiyama J; Koga T; Miyashita T; Izumi Y; Torigoshi T; Motokawa S; Eguchi K; Migita K
Clin Exp Rheumatol; 2010; 28(1):141-2. PubMed ID: 20346255
[No Abstract] [Full Text] [Related]
[Next] [New Search]
